Method of treating neuromyelitis optica spectrum disorder (NMOSD) comprising administering an anti-C5 antibody

A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a human subject in need thereof, comprising administering to the human subject an anti-C5 antibody or antigen binding thereof, wherein the anti-C5 antibody or antigen binding fragment thereof:

• comprises CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs:19, 18 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5 and 6, respectively,
• comprises an Fc region comprising the amino acid sequence set forth in SEQ ID NO:13, wherein the amino acid sequence comprises at most four amino acid substitutions in the amino acid sequence set forth in SEQ ID NO:13, and wherein the amino acid substitutions do not include leucine 307 and serine 313;
• and is administered in an administration cycle comprising:
• (a) once on day 1 at a loading dose of:
• (i) 2400 mg to a subject weighing ≥40 and <60 kg;
• (ii) 2700 mg to a subject weighing ≥60 and <100 kg;
• (iii) 3000 mg to a subject weighing ≥100 kg;
• (b) on day 15 and every eight weeks thereafter at a maintenance dose of:
• (i) 3000 mg to a subject weighing ≥40 and <60 kg;
• (ii) 3300 mg to a subject weighing ≥60 and <100 kg;
• (iii) 3600 mg to a subject weighing ≥100 kg.